Preoperative Serum Carbohydrate Antigen 19-9 Levels Cannot Predict the Surgical Resectability of Pancreatic Cancer: A Meta-Analysis

被引:2
作者
Benke, Marton [1 ]
Farkas, Nelli [2 ,3 ,4 ]
Hegyi, Peter [2 ,5 ,6 ]
Tinusz, Benedek [2 ,3 ]
Sarlos, Patricia [2 ,5 ,7 ]
Eross, Balint [2 ,7 ]
Szemes, Kata [5 ]
Voerhendi, Nora [2 ]
Szakacs, Zsolt [2 ,3 ]
Szuecs, Akos [1 ,2 ]
机构
[1] Semmelweis Univ, Dept Surg 1, Budapest, Hungary
[2] Univ Pecs, Inst Translat Med, Med Sch, Pecs, Hungary
[3] Univ Pecs, Szentagothai Res Ctr, Pecs, Hungary
[4] Univ Pecs, Inst Bioanal, Med Sch, Pecs, Hungary
[5] Univ Pecs, Med Sch, Dept Med 1, Div Gastroenterol, Pecs, Hungary
[6] Univ Szeged, Dept Med 1, Szeged, Hungary
[7] Univ Szeged, Clin Med Doctoral Sch, Szeged, Hungary
关键词
biomarker; prognosis; pancreas adenocarcinoma; carbohydrate antigen 19-9; pancreatic surgery; ADENOCARCINOMA; CA-19-9; MARKERS; CA19-9; MANAGEMENT;
D O I
10.3389/pore.2022.1610266
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Aims: Pancreatic ductal adenocarcinoma has one of the worst prognosis of all malignancies. This investigated the relationship between the preoperative serum carbohydrate antigen 19-9 and surgical resectability. Methods: A systematic search was performed in three databases (MEDLINE, EMBASE, and Web of Science) to compare the surgical resectability of pancreatic ductal adenocarcinoma in patients with high and low preoperative serum carbohydrate antigen 19-9 values. The receiving operating characteristic curves were constructed and the weighted mean differences for preoperative serum carbohydrate antigen 19-9 levels of resectable and unresectable groups of patients were calculated. The PROSPERO registration number is CRD42019132522. Results: Results showed that there was a significant difference in resectability between the low and high carbohydrate antigen 19-9 groups. Six out of the eight studies utilised receiver operating characteristic curves in order to find the cut-off preoperative carbohydrate antigen 19-9 levels marking unresectability. The overall result from the pooled area under curve values from the receiver operating characteristic curves was 0.794 (CI: 0.694-0.893), showing that the preoperative carbohydrate antigen 19-9 level is a "fair " marker of resectability. The result of the pooled weighted mean differences was 964 U/ml (p < 0.001) showing that there is a significant carbohydrate antigen 19-9 difference between the resectable and unresectable groups. Based on the results of the I-squared test, the result was 87.4%, accounting for "considerable " heterogeneity within the population. Conclusion: Carbohydrate antigen 19-9 is not a reliable marker of unresectability, it should not be used on its own in surgical decision-making.
引用
收藏
页数:9
相关论文
共 31 条
[1]   Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies [J].
Adamska, Aleksandra ;
Domenichini, Alice ;
Falasca, Marco .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (07)
[2]   The value of serum carbohydrate antigen 19-9 as a predictor of resectability in pancreatic adenocarcinoma [J].
Albatanony, Ayman A. ;
Alseesi, Alaa A. .
EGYPTIAN JOURNAL OF SURGERY, 2015, 34 (04) :226-229
[3]   Clinical Predictors of Resectability of Pancreatic Adenocarcinoma [J].
Almadi, Majid A. ;
Alharbi, Othman ;
Azzam, Nahla ;
Altayeb, Mohannad ;
Javed, Moammed ;
Alsaif, Faisal ;
Hassanain, Mazen ;
Alsharabi, Abdulsalam ;
Al-Saleh, Khalid ;
Aljebreen, Abdulrahman M. .
SAUDI JOURNAL OF GASTROENTEROLOGY, 2013, 19 (06) :278-285
[4]   The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal [J].
Ballehaninna, Umashankar K. ;
Chamberlain, Ronald S. .
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2012, 3 (02) :105-119
[5]   Role of surgery in pancreatic cancer [J].
Buanes, Trond A. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (21) :3765-3770
[6]  
Chang JC, 2017, INT J MOL SCI, V18, DOI [10.3390/ijms18030667, 10.3390/ijms18071430]
[7]   The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis [J].
Daamen, Lois A. ;
Groot, Vincent P. ;
Goense, Lucas ;
Wessels, Frank J. ;
Rinkes, Inne H. Borel ;
Intven, Martijn P. W. ;
van Santvoort, Hjalmar C. ;
Molenaar, I. Quintus .
EUROPEAN JOURNAL OF RADIOLOGY, 2018, 106 :128-136
[8]   Molecular markers in pancreatic cancer diagnosis [J].
Herreros-Villanueva, Marta ;
Gironella, Meritxel ;
Castells, Antoni ;
Bujanda, Luis .
CLINICA CHIMICA ACTA, 2013, 418 :22-29
[9]   International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017 [J].
Isaji, Shuji ;
Mizuno, Shugo ;
Windsor, John A. ;
Bassi, Claudio ;
Fernandez-del Castillo, Carlos ;
Hackert, Thilo ;
Hayasaki, Aoi ;
Katz, Matthew H. G. ;
Kim, Sun-Whe ;
Kishiwada, Masashi ;
Kitagawa, Hirohisa ;
Michalski, Christoph W. ;
Wolfgang, Christopher L. .
PANCREATOLOGY, 2018, 18 (01) :2-11
[10]   Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests [J].
Jones, CM ;
Athanasiou, T .
ANNALS OF THORACIC SURGERY, 2005, 79 (01) :16-20